Madrigal Pharmaceuticals financials
$509.44−1.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $958.4M | $180.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross profit | $958.4M | $180.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross margin | 100.0% | 100.0% | — | — | — | — | — | — | — | — |
| Operating income | -$300.1M | -$497.9M | -$380.5M | -$293.6M | -$242.5M | -$206.7M | -$95.0M | -$40.7M | -$32.1M | -$25.2M |
| Net income | -$288.3M | -$465.9M | -$373.6M | -$295.4M | -$241.8M | -$202.2M | -$83.9M | -$32.8M | -$31.2M | -$26.4M |
| Net margin | −30.1% | −258.6% | — | — | — | — | — | — | — | — |
| Diluted EPS | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 | $-13.09 | $-5.45 | $-2.22 | $-2.54 | $-5.07 |
| EBITDA | -$298.6M | -$496.8M | -$380.0M | -$293.1M | -$242.1M | -$206.2M | -$94.9M | -$40.6M | -$32.0M | -$25.2M |
| Operating cash flow | -$189.6M | -$455.6M | -$324.2M | -$224.9M | -$183.9M | -$157.6M | -$41.6M | -$25.5M | -$22.3M | -$17.6M |
| Free cash flow | -$190.0M | -$457.0M | -$325.7M | -$225.1M | -$184.1M | -$157.9M | -$41.8M | -$25.5M | -$22.4M | -$17.6M |
| Diluted shares | 22.4M | 21.3M | 18.7M | 17.1M | 16.5M | 15.4M | 15.4M | 14.8M | 12.2M | 5.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $198.7M | $100.0M | $99.9M | $331.5M | $36.3M | $54.0M |
| Short-term investments | $784.9M | $826.2M | $534.2M | $27.2M | $234.1M | $230.1M |
| Total debt | $339.9M | $117.6M | $115.5M | $49.3M | $0.00 | $0.00 |
| Total assets | $1.26B | $1.04B | $640.5M | $362.6M | $273.3M | $287.0M |
| Total liabilities | $656.9M | $287.9M | $235.2M | $165.2M | $77.2M | $47.0M |
| Shareholders' equity | $602.7M | $754.4M | $405.3M | $197.4M | $196.1M | $240.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology